$RLAY News

Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs

Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value

Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?

JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?